Table 1.
Demographic, clinical and laboratory data in patients with pSjD and control subjects.
| Parameter | pSjD Group (N = 17) |
Control Group (N = 17) |
p |
|---|---|---|---|
| Female (N, %) | 16 (94.1) | 16 (94.1) | 0.898 * |
| Age (years) | 56.4 ± 16.8 | 57.0 ± 16.0 | 0.925 † |
| Disease duration (months) | 23.1 ± 17.3 | - | - |
| FS | 1.07 ± 0.82 | ||
| ESSDAI | 1.0 (0.0–2.0) | - | - |
| Schrimer (N, %) | 10 (58.8) | - | - |
| UWS (ml/min) | 0.06 ± 0.11 | - | - |
| SWS (ml/min) | 0.20 ± 0.22 | - | - |
| Dry eyes (N, %) | 12 (70.6) | - | - |
| Dry mouth (N, %) | 15 (88.2) | - | - |
| ANA (N, %) | 13 (76.5) | - | - |
| SSA/Ro52 (N, %) | 10 (58.8) | - | - |
| SSA/Ro60 (N, %) | 9 (52.9) | - | - |
| SSB (N, %) | 6 (35.3) | - | - |
| Cortisol (ng/mL) | 4.69 ± 2.88 | 0.49 ± 0.37 | <0.001 † |
All data are given as whole numbers (percentage), arithmetic mean ± standard deviation or median (interquartile range). * Chi-square test. † Student t-test. Mann–Whitney U test. Abbreviations: ANA, antinuclear antibodies; ESSDAI, EULAR Sjögren’s Syndrome Disease Activity Index; FS, focus score; pSjD, primary Sjögren’s disease; SAA/Ro52, SSA/Ro60, anti-Sjögren’s-syndrome-related antigen A autoantibodies; SSB, anti-Sjögren’s-syndrome-related antigen B autoantibodies; SWS, stimulated whole saliva; UWS, unstimulated whole saliva.